Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?

by Joel D. Leverson, Dan Cojocari
Published 2018-10-01

Potential mechanisms of resistance to venetoclax and strategies to circumvent it

by Stephen K. Tahir, Morey L. Smith, Paul Hessler, Lisa Roberts Rapp, Kenneth B. Idler, Chang H. Park, Joel D. Leverson, Lloyd T. Lam
Published 2017-06-01

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction

by Tareq Saleh, Valerie J. Carpenter, Liliya Tyutyunyk‐Massey, Graeme Murray, Joel D. Leverson, Andrew J. Souers, Moureq R. Alotaibi, Anthony C. Faber, Jason Reed, Hisashi Harada, David A. Gewirtz
Published 2020-10-01

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

by Ioannis K. Zervantonakis, Claudia Iavarone, Hsing-Yu Chen, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula Matulonis, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge
Published 2017-08-01

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

by Jason J. Zoeller, Aleksandr Vagodny, Veerle W. Daniels, Krishan Taneja, Benjamin Y. Tan, Yoko S. DeRose, Maihi Fujita, Alana L. Welm, Anthony Letai, Joel D. Leverson, Vincent Blot, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge
Published 2020-11-01

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA

by Carter K. Fairchild, Konstantinos V. Floros, Sheeba Jacob, Colin M. Coon, Madhavi Puchalapalli, Bin Hu, Hisashi Harada, Mikhail G. Dozmorov, Jennifer E. Koblinski, Steven C. Smith, Gregory Domson, Joel D. Leverson, Andrew J. Souers, Naoko Takebe, Hiromichi Ebi, Anthony C. Faber, Sosipatros A. Boikos
Published 2021-05-01

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

by Heidi M. Haikala, Johanna M. Anttila, Elsa Marques, Tiina Raatikainen, Mette Ilander, Henna Hakanen, Hanna Ala-Hongisto, Mariel Savelius, Diego Balboa, Bjoern Von Eyss, Vilja Eskelinen, Pauliina Munne, Anni I. Nieminen, Timo Otonkoski, Julia Schüler, Teemu D. Laajala, Tero Aittokallio, Harri Sihto, Johanna Mattson, Päivi Heikkilä, Marjut Leidenius, Heikki Joensuu, Satu Mustjoki, Panu Kovanen, Martin Eilers, Joel D. Leverson, Juha Klefström
Published 2019-02-01

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

by Heidi M. Haikala, Johanna M. Anttila, Elsa Marques, Tiina Raatikainen, Mette Ilander, Henna Hakanen, Hanna Ala-Hongisto, Mariel Savelius, Diego Balboa, Bjoern Von Eyss, Vilja Eskelinen, Pauliina Munne, Anni I. Nieminen, Timo Otonkoski, Julia Schüler, Teemu D. Laajala, Tero Aittokallio, Harri Sihto, Johanna Mattson, Päivi Heikkilä, Marjut Leidenius, Heikki Joensuu, Satu Mustjoki, Panu Kovanen, Martin Eilers, Joel D. Leverson, Juha Klefström
Published 2019-02-01

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

by Juliana M. Benito, Laura Godfrey, Kensuke Kojima, Leah Hogdal, Mark Wunderlich, Huimin Geng, Isabel Marzo, Karine G. Harutyunyan, Leonard Golfman, Phillip North, Jon Kerry, Erica Ballabio, Triona Ní Chonghaile, Oscar Gonzalo, Yihua Qiu, Irmela Jeremias, LaKiesha Debose, Eric O’Brien, Helen Ma, Ping Zhou, Rodrigo Jacamo, Eugene Park, Kevin R. Coombes, Nianxiang Zhang, Deborah A. Thomas, Susan O’Brien, Hagop M. Kantarjian, Joel D. Leverson, Steven M. Kornblau, Michael Andreeff, Markus Müschen, Patrick A. Zweidler-McKay, James C. Mulloy, Anthony Letai, Thomas A. Milne, Marina Konopleva
Published 2015-12-01